Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

IMM2510, a differentiated PD-L1xVEGF bispecific antibody with upcoming data in H2 2025. Click to read why TIL is a Hold.

The court determined that Pfizer (NYSE: PFE) and BioNTech’s (NASDAQ: BNTX) Comirnaty vaccine had infringed on this patent, making Moderna eligible for damages for sales after March 2022. In the same ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant.

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

According to Pfizer, "Hundreds of millions of doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally, ...

BioNTech has announced the acquisition of fellow German biotech CureVac in an all-stock transaction valued at approximately $1.25 billion. Under the agreement, CureVac shareholders will receive about ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation.

Throughout the last three months, 11 analysts have evaluated BioNTech BNTX, offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing ...